专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2018029292A1 METHOD FOR TREATING GLIOMA 审中-公开
标题翻译：治疗脑瘤的方法
公开(公告)号：WO2018029292A1
公开(公告)日：2018-02-15
申请号：PCT/EP2017/070288
申请日：2017-08-10
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , UNIVERSITÉ D'ANGERS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： GAVARD, Julie , HARFORD-WRIGHT, Elisabeth , BIDERE, Nicolas
IPC分类号： A61K31/704 , A61K31/555 , A61K31/519 , A61P35/00 , A61K45/06 , A61K36/77
摘要： The present invention relates to the treatment of glioma. Considering the potential of anti-GIC therapies to advance GBM treatment, the inventors employed a chemical screen of currently FDA- and EM A- approved small molecules in order to identify a selective inhibitor of GIC (the four genetic subtypes of GBM) expansion with known bio-safety in humans. The cytotoxic effect of the compounds was initially evaluated in two patient-derived GIC growing as spheres and identified β-escin, a mixture of triterpenoid saponins isolated from the seeds of horse chestnuts. They demonstrated a specific effect of β-escin on induction of apoptosis and modulation of sternness properties of nine individual GIC, indicating the potential of β-escin as a selective and potent inhibitor of GIC. Thus the invention relate to an escin family compound (and particularly β-escin) for use in the treatment of glioma.
摘要翻译：本发明涉及神经胶质瘤的治疗。考虑到抗GIC疗法促进GBM治疗的潜力，本发明人使用目前FDA和EMA批准的小分子的化学筛选以鉴定已知的选择性GIC（四种GBM遗传亚型）扩增剂的抑制剂人类的生物安全。化合物的细胞毒性作用最初在两个患者衍生的GIC中作为球体进行评估，并鉴定出β-七叶树素，即从栗子种子中分离出的三萜皂苷的混合物。他们证明了β-七叶素对诱导细胞凋亡和调节九个单独GIC的严重性的特异性作用，表明β-七叶素作为选择性和有效的GIC抑制剂的潜力。因此，本发明涉及用于治疗神经胶质瘤的七叶素家族化合物（特别是β-七叶皂苷）。

22. 发明申请

WO2016198500A1 METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HUMAN CYTOMEGALOVIRUS (HCMV) INFECTION 审中-公开
标题翻译：用于人造血细胞病毒（HCMV）感染的RNA指导治疗的方法和组合物
公开(公告)号：WO2016198500A1
公开(公告)日：2016-12-15
申请号：PCT/EP2016/063108
申请日：2016-06-09
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES
发明人： HASPOT, Fabienne , GERGEN, Janina , COULON, Flora , HALARY, Franck
IPC分类号： C12N15/113 , A61K31/7088 , C12N9/22 , A61P31/00
CPC分类号： C12N15/1133 , C12N2310/10 , C12N2310/20
摘要： The invention relates to methods and compositions for treatment of human cytomegalovirus (HCMV) infection. The compositions include isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and one or more guide RNA, wherein the guide RNA is complementary to a particular target sequence in the HCMV genome.
摘要翻译：本发明涉及用于治疗人巨细胞病毒（HCMV）感染的方法和组合物。组合物包括分离的核酸序列，其包含与CRISPR相关的内切核酸酶和一种或多种引导RNA，其中引导RNA与HCMV基因组中的特定靶序列互补。

23. 发明申请

WO2016131959A1 USE OF A LAMININ FOR DIFFERENTIATING PLURIPOTENT CELLS INTO HEPATOCYTE LINEAGE CELLS 审中-公开
标题翻译：用于将PLUIPOTENT细胞分化为肝细胞系细胞的LAMININ的使用
公开(公告)号：WO2016131959A1
公开(公告)日：2016-08-25
申请号：PCT/EP2016/053560
申请日：2016-02-19
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES
发明人： NGUYEN, Tuan Huy , FOURRIER, Angélique
IPC分类号： C12N5/071
CPC分类号： C12N5/0672 , C12N5/067 , C12N2500/98 , C12N2501/119 , C12N2501/12 , C12N2501/155 , C12N2501/16 , C12N2501/237 , C12N2501/415 , C12N2501/727 , C12N2506/45 , C12N2533/52
摘要： The invention relates to the use of a laminin (LN) as a matrix for hepatic differentiation. The invention also relates to a method for inducing hepatic differentiation comprising the steps of: (i) providing a population of human pluripotent cells, (ii) culturing the population on a support coated with a laminin in a endoderm induction medium to produce a population of human DE cells, (iii) culturing said population of human DE cells on a support coated with a laminin in a hepatic induction medium to produce a population of human hepatoblasts-like cells, and (iv) optionally culturing said population of human hepatoblasts-like cells on a support coated with a laminin in a hepatic maturation medium to produce a population of human hepatocyte-like cells. The invention further relates to a population of human hepatoblasts-like cells or human fetal hepatocyte-like cells obtained by the method of the invention. The invention further relates to a population of human hepatoblasts-like cells expressing HNF4 α and expressing substantially AFP for use in a method of treatment of the human body.
摘要翻译：本发明涉及层粘连蛋白（LN）作为肝分化基质的用途。本发明还涉及诱导肝分化的方法，其包括以下步骤：（i）提供人多能细胞群体，（ii）在涂覆有内皮细胞的内皮细胞诱导培养基上的支持物上培养群体以产生群体人DE细胞，（iii）在肝诱导培养基中培养包被有层粘连蛋白的载体上的所述人DE细胞群以产生人成肝细胞样细胞群，和（iv）任选培养所述人类成肝细胞样细胞在肝成熟培养基中涂覆有层粘连蛋白的支持物上的细胞以产生人类肝细胞样细胞群体。本发明还涉及通过本发明的方法获得的人类成肝细胞样细胞或人类胎肝细胞样细胞群。本发明还涉及一种人类成肝细胞样细胞群体，其表达HNF4α并且基本上表达用于人体治疗方法的AFP。

24. 发明申请

WO2016066618A3 COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC TOLERANCE 审中-公开
标题翻译：抗原特异性耐受的组合物和方法
公开(公告)号：WO2016066618A3
公开(公告)日：2016-05-06
申请号：PCT/EP2015/074819
申请日：2015-10-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , ONIRIS
发明人： ANEGON, Ignacio , BLANCOU, Philippe , SIMON, Thomas , POGU, Julien
IPC分类号： A61K39/00 , A61K31/409 , A61K31/555
摘要： The invention is in the field of immunotherapy. More particularly, the invention provides a composition comprising a Heme Oxygenase- 1 (HO-1) and antigens. Also provided herein are methods of administering the compositions of the invention by subcutaneous, intradermal or topical administration in a patient for inducing antigen-specific tolerance.
摘要翻译：本发明属于免疫疗法领域。更具体地说，本发明提供了包含血红素加氧酶-1（HO-1）和抗原的组合物。本文还提供了通过在患者中皮下，皮内或局部施用以诱导抗原特异性耐受来施用本发明组合物的方法。

25. 发明申请

WO2015181394A1 NOVEL IL-2/IL-15 RECEPTOR ANTAGONIST COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES OR GRAFT REJECTION 审中-公开
标题翻译：新型IL-2 / IL-15受体拮抗剂化合物及其用于治疗自身免疫和炎症疾病或损伤的药物
公开(公告)号：WO2015181394A1
公开(公告)日：2015-12-03
申请号：PCT/EP2015/062167
申请日：2015-06-01
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , UNIVERSITÉ D'ANGERS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： JACQUES, Yannick , QUEMENER, Agnès , MORTIER, Erwan , MATHE-ALLAINMAT, Monique , DUBREUIL, Didier , LEBRETON, Jacques , MAILLASSON, Mike
IPC分类号： C07D403/12
CPC分类号： C07D403/12
摘要： Novel IL-2/IL-15 Receptor antagonist compounds and uses thereof for the treatment of autoimmune and inflammatory diseases or graft rejection Novel IL-2/IL-15 Receptor antagonist compounds and uses thereof for the treatment of autoimmune and inflammatory diseases or graft rejection. The invention relates to a compound of general formula (1) wherein X represents O, S or NR 4 , wherein R 4 is alkyl; A is selected from S, SO, SO 2 , NH and O; Y represents (CR 5 R 6 ) n or (CR 5 R 6 O) n , wherein R 5 and R 6 identical or different are H or alkyl and n represents an integer from 1 to 15; R 1 represents a 5 to 10 membered aromatic or non-aromatic mono-or bicyclic, 1 optionally bridged ring, R 2 is C 1 -C 4 alkyl; R 3 is H or alkyl; p is 0 or 1; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of the interactions of IL-2/15 to IL-2/15Rβand hence useful in the treatment of an autoimmune or an inflammatory diseases and graft rejection.
摘要翻译：新型IL-2 / IL-15受体拮抗剂化合物及其用于治疗自身免疫性和炎性疾病或移植排斥的新用途IL-2 / IL-15受体拮抗剂化合物及其用于治疗自身免疫性和炎性疾病或移植排斥。本发明涉及通式（1）的化合物，其中X代表O，S或NR4，其中R4是烷基; A选自S，SO，SO2，NH和O; Y表示（CR5R6）n或（CR5R6O）n，其中R5和R6相同或不同是H或烷基，n表示1至15的整数; R1表示5至10元芳族或非芳族单或双环1任选桥连的环，R 2为C 1 -C 4烷基; R3是H或烷基; p为0或1; 或其药学上可接受的盐。本发明的化合物是IL-2/15与IL-2 /15Rβ相互作用的抑制剂，因此可用于治疗自身免疫或炎性疾病和移植排斥反应。

26. 发明申请

WO2015177329A1 METHODS FOR DETERMINING WHETHER A PATIENT WILL ACHIEVE A RESPONSE AFTER RADIATION THERAPY 审中-公开
标题翻译：用于确定患者在辐射治疗后应答反应的方法
公开(公告)号：WO2015177329A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/061354
申请日：2015-05-22
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , UNIVERSITÉ D'ANGERS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT DE CANCÉROLOGIE DE L'OUEST - SITE RENÉ GAUDUCHEAU
发明人： PARIS, François , DUBOIS, Nolwenn , RIO, Emmanuel , RIPOCHE, Natacha
IPC分类号： G01N33/50 , C12Q1/48
CPC分类号： G01N33/5011 , C12Q1/48 , G01N33/5008 , G01N33/502 , G01N33/92 , G01N2560/00
摘要： The present invention relates to methods for determining whether a patient will achieve a response after radiation therapy. In particular, the present invention relates to a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy comprising the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).
摘要翻译：本发明涉及用于确定患者是否将在放射治疗之后实现应答的方法。特别地，本发明涉及一种用于确定患有癌症的患者是否将在放射治疗之后达到应答的方法，包括以下步骤：i）确定在放射治疗之前从患者获得的第一血液样品中的神经酰胺水平， ii）确定在放射治疗期间或之后从患者获得的第二血液样品中的神经酰胺水平，iii）将步骤i）中确定的水平与在步骤ii）确定的水平进行比较，以及iv）断定患者将实现当在步骤ii）确定的水平高于在步骤i）确定的水平时，或者得出当步骤ii）确定的水平低于在步骤i）确定的水平时患者将不会达到响应的响应。

27. 发明申请

WO2015001082A1 NOVEL ALTERNATIVE SPLICE TRANSCRIPTS FOR MHC CLASS I RELATED CHAIN ALPHA (MICA) AND USES THEREOF 审中-公开
标题翻译： MHC I类相关链ALPHA（MICA）及其用途的新型替代性码词
公开(公告)号：WO2015001082A1
公开(公告)日：2015-01-08
申请号：PCT/EP2014/064316
申请日：2014-07-04
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , CHU DE NANTES
发明人： CHARREAU, Béatrice , GERARD, Nathalie , TONNERRE, Pierre , GAVLOVSKY, Pierre-Jean
IPC分类号： C07K14/47 , C12N5/00 , A61K38/00
CPC分类号： C07K14/70539 , C07K14/7056 , C07K2319/30 , C12Q1/6883 , C12Q2600/156 , C12Q2600/172 , G01N33/6893
摘要： The present invention relates to novel alternative splice transcripts (AST) for MICA (MHC class I related chain alpha) encoding novel MICA protein isoforms and uses thereof. In particular, the present invention relates to an isolated polypeptide at least 80% of identity with a sequence selected from the group consisting of SEQ ID NO:1 (MICA-A), SEQ ID NO:2 (MICA-B1), SEQ ID NO:3 (MICA-B2); SEQ ID NO:4 (MICA-C) and SEQ ID NO: (MICA-D).
摘要翻译：本发明涉及用于编码新型MICA蛋白质亚型的MICA（MHC I类相关链α）的新型替代剪接转录物（AST）及其用途。特别地，本发明涉及与选自SEQ ID NO：1（MICA-A），SEQ ID NO：2（MICA-B1），SEQ ID NO：1（SEQ ID NO：1））的序列具有至少80％同一性的分离多肽 NO：3（MICA-B2）; SEQ ID NO：4（MICA-C）和SEQ ID NO：（MICA-D）。

28. 发明申请

WO2014191471A1 MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES 审中-公开
标题翻译：用PARCINSONIAN综合征治疗神经病变疾病的细胞内氯离子浓度调节剂
公开(公告)号：WO2014191471A1
公开(公告)日：2014-12-04
申请号：PCT/EP2014/061092
申请日：2014-05-28
申请人： NEUROCHLORE , CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ D'AIX-MARSEILLE , UNIVERSITÉ DE NANTES
发明人： BEN-ARI, Yehezkel , DEHORTER, Nathalie , DAMIER, Philippe , HAMMOND, Constance
IPC分类号： C12N15/113 , A61K31/341
CPC分类号： A61K31/196 , A61K31/192 , A61K45/06 , C12N15/1138 , A61K2300/00
摘要： The present invention relates to a composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein said composition comprises an effective amount of a modulator of a chloride transporter.
摘要翻译：本发明涉及在有需要的受试者中用于治疗帕金森综合征的神经变性疾病的组合物，其中所述组合物包含有效量的氯化物转运蛋白的调节剂。

29. 发明申请

WO2013045844A1 PROCEDE DE SOUDAGE ET DE RECHARGEMENT DE PIECES METALLIQUES EN ALUMINIUM PAR UN PROCEDE MIG AVEC COURANT ET FIL D'APPORT PULSES 审中-公开
标题翻译：使用具有脉冲电流和脉冲填充线的MIG工艺焊接和建立铝的金属组件的方法
公开(公告)号：WO2013045844A1
公开(公告)日：2013-04-04
申请号：PCT/FR2012/052184
申请日：2012-09-27
申请人： SNECMA , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ PARIS SUD (UPS) , UNIVERSITÉ DE NANTES , MOTTIN, Jean-Baptiste , CASTAGNE, Jean-François , BAUDIN, Thierry , BENOIT, Alexandre Yann Michel , PAILLARD, Pascal
发明人： MOTTIN, Jean-Baptiste , CASTAGNE, Jean-François , BAUDIN, Thierry , BENOIT, Alexandre Yann Michel , PAILLARD, Pascal
IPC分类号： B23K9/09 , B23P6/04 , F01D25/24 , B23K9/04 , B23K26/34
CPC分类号： B23K9/173 , B23K9/04 , B23K9/046 , B23K9/09 , B23K26/32 , B23K26/342 , B23K35/0261 , B23K35/286 , B23K2201/001 , B23K2203/08 , B23K2203/10 , B23K2203/18 , B23K2203/20 , B23P6/007 , F01D21/045 , F01D25/243 , F05D2230/235 , F05D2230/30 , F05D2230/80
摘要： La présente invention concerne un procédé de rechargement de pièces métalliques en aluminium de turbomachine au moyen d'un appareillage de soudage MIG comportant un générateur de courant pulsé et un débit de fil de métal d'apport pulsé, ledit procédé étant caractérisé en ce que ledit rechargement est réalisé au moyen d'un fil de métal d'apport dont la composition est de même nature que la composition de l'alliage d'aluminium de ladite pièce à recharger, ledit débit de fil de métal pulsé et la vitesse de rechargement de ladite pièce métallique de turbomachine étant adaptés de manière à réaliser un rechargement sans fissuration à chaud.
摘要翻译：本发明涉及使用包括脉冲电流发生器和金属填充线的脉冲进料的MIG焊接装置来建立由铝制成的金属涡轮机组件的方法，所述方法的特征在于，所述构建使用金属填充线的组成与所建立的所述部件的铝合金的组成相同，所述金属线的脉冲进料和所述金属涡轮机组件的建立速率适应于在热状态下实现积聚而不破裂。

30. 发明申请

WO2022053691A1 METHOD TO TREAT AND STRATIFICATE A PATIENT SUFFERING FROM A CANCER 审中-公开
公开(公告)号：WO2022053691A1
公开(公告)日：2022-03-17
申请号：PCT/EP2021/075132
申请日：2021-09-13
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , INSTITUT DE CANCÉROLOGIE DE L'OUEST , UNIVERSITÉ DE NANTES
发明人： CARTRON, Pierre-François , BOUGRAS-CARTRON, Gwenola
IPC分类号： C12Q1/6886
摘要： The present invention relates to the stratification and treatment of patients suffering of cancer. Due to the fact that anti-PD1 therapy targets lymphocytes and the efficiency of anti-cancer therapy is measured by the impact on the tumor cells, the inventors postulated that studying the molecular mechanisms of resistance of anti-PD1 therapy should take into consideration existing intercellular communication between lymphocytes and tumor cells. As exosomes are the carriers for the intercellular transfer of the miRNA responsible of chemoresistance, they herein investigated whether exposure of T cells to anti-PD1 therapy might promote the expression of exosomal miRNA (exomiR) causing the chemoresistance of cancer cells. Surprisingly, they found that anti-PD1 exposure of T-cell promotes an enrichment of exosomal miRNA-4315. They also noted that exosomal miRNA-4315 induced a phenomenon of apopto-resistance to conventional chemotherapies in cancer cells receiving exosomal miRNA-4315. At molecular level, they discern that the apopto-resistance phenomenon was associated with the miRNA-4315-mediated down-regulation of Bim, a pro-apoptotic protein. In cellular and mice models, they observed that the BH3 mimetic agent ABT263 circumvented this resistance. Thus, the invention relates to methods of stratification using exosomal miRNA-4315 and method of treatment of patients suffering of cancer using BH3 mimetic agent.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式